Boceprevir, Peg-interferon alfa 2b and Ribavirin
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HCV Coinfection
Conditions
HCV Coinfection, HIV-1 Infection
Trial Timeline
May 1, 2011 → May 1, 2014
NCT ID
NCT01335529About Boceprevir, Peg-interferon alfa 2b and Ribavirin
Boceprevir, Peg-interferon alfa 2b and Ribavirin is a phase 2 stage product being developed by Merck for HCV Coinfection. The current trial status is completed. This product is registered under clinical trial identifier NCT01335529. Target conditions include HCV Coinfection, HIV-1 Infection.
What happened to similar drugs?
2 of 3 similar drugs in HCV Coinfection were approved
Approved (2) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01335529 | Phase 2 | Completed |
Competing Products
3 competing products in HCV Coinfection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VEKIRAX + EXVIERA | AbbVie | Approved | 43 |
| Peginterferon Alfa-2 | Roche | Phase 3 | 32 |
| Maraviroc + Placebo | Pfizer | Approved | 43 |